MedDataX Logo

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

NCT ID: NCT00303524

Last Updated: 2009-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3 monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol suppression in patients with oestrogen receptor positive early breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

NCT01073865

Breast Cancer
COMPLETED PHASE3

Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex

NCT00235937

Breast Cancer
COMPLETED PHASE2

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

NCT03936933

Breast Cancer
TERMINATED PHASE3

Zoladex Plus Tamoxifen in Breast Cancer

NCT00827307

Mammography Estrogen Lipemia +2 more
COMPLETED NA

Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy

NCT00888082

Breast Cancer Ovarian Function
WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Zoladex 3-month depot

Group Type EXPERIMENTAL

Goserelin acetate

Intervention Type DRUG

injection 10.8 mg every 3 months

2

Zoladex 1-month depot

Group Type EXPERIMENTAL

Goserelin acetate

Intervention Type DRUG

Injection 3.6 mg monthly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Goserelin acetate

Injection 3.6 mg monthly

Intervention Type DRUG

Goserelin acetate

injection 10.8 mg every 3 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zoladex Zoladex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pre-menopausal women aged 20 years or over with histological/cytologically-confirmed ER +ve breast cancer who have undergone radical surgery and WHO performance status 0,1 or 2.

Exclusion Criteria

* Evidence of metastatic disease, previous bilateral oophorectomy or radiotherapy to the ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting trial treatment, previous neo-adjuvant/adjuvant hormonal breast cancer therapy
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca Japan Medical Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Chiba, , Japan

Site Status

Research Site

Fukuoka, , Japan

Site Status

Research Site

Fukushima, , Japan

Site Status

Research Site

Isehara, , Japan

Site Status

Research Site

Kagoshima, , Japan

Site Status

Research Site

Kashiwa, , Japan

Site Status

Research Site

Kawasaki, , Japan

Site Status

Research Site

Kitakyushu, , Japan

Site Status

Research Site

Kumamoto, , Japan

Site Status

Research Site

Matsuyama, , Japan

Site Status

Research Site

Miyazaki, , Japan

Site Status

Research Site

Nagoya, , Japan

Site Status

Research Site

Niigata, , Japan

Site Status

Research Site

Osaka, , Japan

Site Status

Research Site

Ōta-ku, , Japan

Site Status

Research Site

Saitama, , Japan

Site Status

Research Site

Sayama, , Japan

Site Status

Research Site

Shimotsuke, , Japan

Site Status

Research Site

Suita, , Japan

Site Status

Research Site

Tokorozawa, , Japan

Site Status

Research Site

Tokyo, , Japan

Site Status

Research Site

Utsunomiya, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Zoladex EBC Study

Identifier Type: -

Identifier Source: secondary_id

D8664C00004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
NCT00186121 COMPLETED PHASE2
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
NCT00107263 COMPLETED PHASE3
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
NCT00050011 COMPLETED PHASE3
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
NCT00171340 COMPLETED PHASE3
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
NCT00031850 COMPLETED NA
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
NCT01654367 UNKNOWN PHASE2/PHASE3
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
NCT00429403 TERMINATED PHASE3
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
NCT00605267 COMPLETED PHASE3
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
NCT00305448 COMPLETED PHASE2
Adjuvant AI Combined With Zoladex
NCT01352091 UNKNOWN PHASE3
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
NCT00376740 COMPLETED PHASE3
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
NCT00237198 COMPLETED PHASE2
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
NCT00332709 COMPLETED PHASE3
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
NCT03238703 WITHDRAWN PHASE4
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
NCT03176238 COMPLETED PHASE3
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
NCT00171314 COMPLETED PHASE3
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
NCT00903162 COMPLETED PHASE2
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
NCT01149356 TERMINATED PHASE1
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
NCT00295646 COMPLETED PHASE3
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
NCT00332852 COMPLETED PHASE3
Letrozole in Preventing Breast Cancer in Postmenopausal Women
NCT00090857 COMPLETED PHASE2
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
NCT02463032 COMPLETED PHASE2
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395 ACTIVE_NOT_RECRUITING PHASE3
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
NCT00329940 COMPLETED PHASE3
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
NCT00303615 TERMINATED PHASE2